Longer duration of bisphosphonate therapy is associated with a hi

Longer duration of bisphosphonate therapy is associated with a higher risk of atypical femur fractures. Combination therapy with teriparatide and denosumab appears to increase bone mineral density to a greater extent than either therapy alone in postmenopausal women at high risk for fracture. There are several novel therapies under investigation for the treatment of osteoporosis, which are in various stages of development. Nonadherence to osteoporosis therapies continues to be a major problem in selleck chemicals clinical practice.SummaryThere are numerous effective pharmacologic treatment

options for postmenopausal osteoporosis. Bisphosphonate drug holidays continue to be an area of significant debate.”
“BackgroundMany patients treated with oral anticoagulants for atrial fibrillation undergo percutaneous stent implantation, where dual antiplatelet therapy (DAPT) is also recommended. The current evidence to support triple oral antithrombotic

buy MGCD0103 therapy (TOAT) in these patients is limited, and new strategies are being discussed to optimize outcomes.

HypothesisThere will be variation in antithrombotic strategies in patients with atrial fibrillation needing stenting.

MethodsWe surveyed US-based cardiologists serving as clinical investigators in academic sites and posted an online question of the month on .

ResultsSeventy-five (10.7%) responses were received to the email survey and 119 to the online question. Bare-metal stenting (BMS) was a priori preferred over drug-eluting stenting (DES) for 50.6% of patients. Only 8.8% of the responders chose newer anticoagulants in addition to DAPT as the preferred oral anticoagulant. For duration of TOAT, 79.4% of physicians recommended stopping

DAPT at 1 month when BMS was used in patients presenting without acute coronary syndrome (ACS) vs 57.4% in patients with ACS. In patients implanted learn more with a DES, 73.5% and 76.5% preferred stopping DAPT at 6 to 12 months (no ACS vs ACS, respectively). When asked which of the 2 antiplatelet agents they would recommend stopping after the above durations, 50% chose to quit aspirin.

ConclusionsThe survey highlights an interest in the new strategy of dropping aspirin, but the lack of concrete evidence triggers undesired diversity in clinical approaches. High-quality data on the efficacy and safety of such interventions are needed to further consolidate these approaches.”
“Purpose of review

To examine recent advances in the pathophysiology and therapy of pediatric vasculitis.

Recent findings

The past 2 years have been marked by significant progress in extending novel techniques to the investigation of the two most common pediatric vasculitis syndromes, Henoch-Schonlein purpura. and Kawasaki disease. Study of other vasculitides, such as Wegener granulomatosis, Churg-Strauss syndrome, and microscopic polyangiitis, is impeded by the small number of pediatric patients.

Comments are closed.